Sun Pharmaceutical Industries Ltd - Company Profile
Powered by 
All the sales intelligence you need on Sun Pharmaceutical Industries Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sun Pharmaceutical Industries Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sun Pharmaceutical Industries Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sun Pharmaceutical Industries Ltd (Sun Pharma) is a specialty pharmaceutical company that offers an array of pharmaceutical formulations such as branded generics and generic pharmaceuticals. The company’s portfolio includes products for the treatment of psychiatry, orthopaedic, diabetology, gastroenterology, anti-infectives, neurology, cardiology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. The company carries out product development, process chemistry, and manufacture of complex formulations, active pharmaceutical ingredients (APIs) and over-the-counter products. It offers drugs in various dosage forms such as tablets, inhalers, ointments, capsules, injectables, creams, and liquids. Sun Pharma is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
Sun House, CTS No. 201 B/1, Western Express Highway, East Goregaon, Mumbai, Maharashtra, 400063
Website
https://sunpharma.com/
Telephone
91 22 43244324
No of Employees
47,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SUNPHARMA (NSE)
Revenue (2025)
$6.7B
11.2%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
5%
(2025 vs 2024)
Market Cap*
$47.8B
Net Profit Margin (2025)
XYZ
-5.5%
(2025 vs 2024)
* As of and is in US$
Sun Pharmaceutical Industries Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | Amixide |
| Generics | Anabrez |
| Branded Generics | Arpizol |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In July, the company launched generic semaglutide, a GLP-1 receptor agonist in South Africa for the treatment of adults with type 2 diabetes. |
| 2026 | Regulatory Approval | In July, the company received approval from Brazil’s ANVISA to manufacture and market injectable semaglutide pens for treating adults with poorly controlled type 2 diabetes. |
| 2026 | Regulatory Approval | In July, the company received approval from the South African Health Products Regulatory Authority to manufacture and market a generic version of semaglutide injection to treat adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise. |
Competitor Comparison
| Key Parameters | Sun Pharmaceutical Industries Ltd | Pfizer Inc | Viatris Inc | Stada Arzneimittel AG | Dr. Reddy's Laboratories Ltd |
|---|---|---|---|---|---|
| Headquarters | India | United States of America | United States of America | Germany | India |
| City | Mumbai | New York City | Canonsburg | Bad Vilbel | Hyderabad |
| State/Province | Maharashtra | New York | Pennsylvania | Hessen | Telangana |
| No. of Employees | 47,000 | 75,000 | 30,000 | 11,649 | 27,527 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dilip S. Shanghvi | Chairman | Executive Board | - | - |
| Aalok D. Shanghvi | Chief Operating Officer | Executive Board | 2025 | - |
| Suresh Kumar Rai | Chief Human Resources Officer | Senior Management | 2023 | - |
| Jayashree Satagopan | Chief Financial Officer | Senior Management | 2025 | - |
| Dheeraj Sinha | Chief Information Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer